| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
N6-Cyclohexyladenosine targets the adenosine A1 receptor, a G protein-coupled receptor that is widely distributed in the central nervous system, heart, and other tissues. Activation of the A1 receptor by N6-cyclohexyladenosine inhibits adenylyl cyclase, reduces cAMP levels, and modulates various downstream signaling pathways. The compound is a potent and selective A1 receptor agonist.
|
|---|---|
| ln Vitro |
In vitro, N6-cyclohexyladenosine has been shown to activate adenosine A1 receptors in various cell systems. It inhibits adenylyl cyclase activity and reduces cAMP accumulation. It can modulate neurotransmitter release, neuronal excitability, and other cellular processes. The compound's effects can be blocked by A1 receptor antagonists.
|
| ln Vivo |
In vivo, N6-cyclohexyladenosine has been studied for its effects on cardiovascular function, including bradycardia and hypotension. It also has effects on the central nervous system, including sedation, anticonvulsant activity, and analgesia. The compound has been used to study the role of A1 receptors in various physiological and pathological conditions.
|
| Enzyme Assay |
For non-cellular receptor binding assays, N6-cyclohexyladenosine can be evaluated for affinity to adenosine A1 receptors using radioligand binding assays. Competitive binding experiments using [³H]DPCPX or other labeled ligands are performed. For functional assays, the compound's ability to activate A1 receptors can be assessed by measuring inhibition of cAMP accumulation.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing adenosine A1 receptors are cultured and treated with N6-cyclohexyladenosine. Receptor activation is measured by cAMP accumulation or other downstream signaling events. The compound's effects on cell proliferation, differentiation, and gene expression can also be assessed.
|
| Animal Protocol |
For in vivo animal studies, N6-cyclohexyladenosine can be administered to animal models. Cardiovascular parameters such as heart rate and blood pressure are measured. Behavioral assays for sedation, anticonvulsant activity, and analgesia can be performed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N6-cyclohexyladenosine include solubility in DMSO and ethanol. As an adenosine analog, it is rapidly metabolized and may have a short half-life.
|
| Toxicity/Toxicokinetics |
The toxicological profile of N6-cyclohexyladenosine has not been fully characterized. As a potent A1 receptor agonist, it may cause cardiovascular and central nervous system effects at higher doses.
|
| Additional Infomation |
N6-Cyclohexyladenosine is a potent and selective adenosine A1 receptor agonist. It is used in pharmacological research to study the role of A1 receptors in various physiological and pathological processes. It has effects on cardiovascular function, neurotransmission, and pain modulation.
|
| Molecular Formula |
C16H23N5O4
|
|---|---|
| Molecular Weight |
349.38492
|
| Exact Mass |
349.175
|
| CAS # |
36396-99-3
|
| PubChem CID |
9841284
|
| Appearance |
White to off-white solid powder
|
| Density |
1.71g/cm3
|
| Boiling Point |
675.2ºC at 760mmHg
|
| Flash Point |
362.1ºC
|
| Index of Refraction |
1.787
|
| LogP |
0.255
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
452
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCCC4)O1)O)O
|
| InChi Key |
SZBULDQSDUXAPJ-XNIJJKJLSA-N
|
| InChi Code |
InChI=1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~286.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8622 mL | 14.3111 mL | 28.6221 mL | |
| 5 mM | 0.5724 mL | 2.8622 mL | 5.7244 mL | |
| 10 mM | 0.2862 mL | 1.4311 mL | 2.8622 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
